Memento Medicines launched with a $93 million Series A financing and licensing of a lead program focused on retinal diseases. The company’s initial pipeline emphasis on ophthalmology points to a selective, single-indication strategy built around a licensed therapeutic program for retinal pathology, supported by substantial early capital. The launch adds another well-capitalized candidate development shop aiming to convert platform and IP access into clinical progress in sight-threatening conditions.